Isoray - Innovative Brachytherapy

Dr. Brian Moran: Brachytherapy: An Innovative Disruptor

Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field.

Dr. Moran stresses how important it is for clinicians to recognize the value of brachytherapy and promote it in order to carry it forward. Low-dose rate brachytherapy has been very threatening to other practice modalities in the past, yet it has endured through an environment in which it has only been promoted by the experts and community physicians who practice it.

Dr. Moran explains how brachytherapy has taken full advantage of today’s technology to bring patients the best care possible and the best results. “Many of the doctors have worked hard and we’ve learned as we’ve gone,” says Moran. And he is obviously excited about what the future holds.

The Merger: Paving the Way for Tomorrow

The Merger: Paving the Way for Tomorrow

By CEO Lori Woods We began this journey with a simple truth. Standing still is never an option. And the history of Isoray underscores that reality. When Isoray was founded, we were focused on the treatment of prostate cancer utilizing Cesium-131. Some saw it as a...

read more
It’s the Details That Make Cesium-131 The Better Choice

It’s the Details That Make Cesium-131 The Better Choice

By Peter T. Heiberger, M.S. DABR, RSOLead Medical Physicist, Radiation Oncology, Aurora Health Care, Green Bay, WI When I think about Cesium-131 an old expression comes to mind. “It's the little details that are vital. Little things make big things happen.” When it...

read more
Lessons Learned About Cesium-131

Lessons Learned About Cesium-131

By Brian J. Moran, M.D. FABSMedical Director, Prostate Cancer Foundation of Chicago I am a radiation oncologist who, like many of you, has always looked for opportunities to do more for those I treat. That is how I first learned about Cesium-131 brachytherapy. In the...

read more